ZA991922B - Novel compositions of eprosartan. - Google Patents

Novel compositions of eprosartan.

Info

Publication number
ZA991922B
ZA991922B ZA9901922A ZA991922A ZA991922B ZA 991922 B ZA991922 B ZA 991922B ZA 9901922 A ZA9901922 A ZA 9901922A ZA 991922 A ZA991922 A ZA 991922A ZA 991922 B ZA991922 B ZA 991922B
Authority
ZA
South Africa
Prior art keywords
eprosartan
novel compositions
composition
solvate
hydrate
Prior art date
Application number
ZA9901922A
Other languages
English (en)
Inventor
Gopadi M Venkatesh
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ZA991922B publication Critical patent/ZA991922B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
ZA9901922A 1998-03-11 1999-03-10 Novel compositions of eprosartan. ZA991922B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7766098P 1998-03-11 1998-03-11

Publications (1)

Publication Number Publication Date
ZA991922B true ZA991922B (en) 1999-09-13

Family

ID=22139347

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901922A ZA991922B (en) 1998-03-11 1999-03-10 Novel compositions of eprosartan.

Country Status (21)

Country Link
EP (1) EP1061803B1 (fr)
JP (1) JP2002506010A (fr)
KR (1) KR20010041796A (fr)
CN (1) CN1299235A (fr)
AT (1) ATE508633T1 (fr)
AU (1) AU757547B2 (fr)
BR (1) BR9908691A (fr)
CA (1) CA2323363C (fr)
CY (1) CY1111738T1 (fr)
CZ (1) CZ303067B6 (fr)
DK (1) DK1061803T3 (fr)
ES (1) ES2366394T3 (fr)
HU (1) HU228574B1 (fr)
IL (1) IL138345A (fr)
NO (1) NO331207B1 (fr)
NZ (1) NZ506700A (fr)
PL (1) PL192545B1 (fr)
SI (1) SI1061803T1 (fr)
TR (1) TR200002646T2 (fr)
WO (1) WO1999045779A1 (fr)
ZA (1) ZA991922B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213638C (fr) 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols contenant des dispersions de nanoparticules
BR9912145A (pt) * 1998-07-20 2001-09-25 Smithkline Beecham Corp Formulações bioaperfeiçoadas contendo eprosartan em forma de dosagem sólida oral
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
JP2003530343A (ja) * 2000-04-12 2003-10-14 ノバルティス アクチエンゲゼルシャフト アルドステロンシンターゼインヒビター単体またはat1−レセプターアンタゴニストとの組み合わせの新規医薬使用
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (fr) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Utilisation d'un agent bloquant du récepteur AT1 de l'angiotensine II, seul ou combiné avec un thiazide ou l'angiotensine II dans le traitement des accidents vasculaires cérébraux
AU2004206109A1 (en) * 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Co-precipitated amorphous losartan and dosage forms comprising the same
AU2004208615C1 (en) 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
RU2384346C2 (ru) * 2004-06-23 2010-03-20 Зольвай Фармасьютиклз Гмбх Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
WO2006136916A2 (fr) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Particules micronisees sensiblement pures de telmisartan et compositions pharmaceutiques renfermant celles-ci
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
EP2181109A4 (fr) * 2007-07-25 2011-08-03 Hetero Drugs Ltd Particules cristallines de mésylate d'éprosartan et procédé de préparation d'éprosartan pur
EP2108365A1 (fr) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Formule pharmaceutique à dosage simple comportant du mesylate d'eprosartan
CN103705510A (zh) * 2013-12-27 2014-04-09 华润赛科药业有限责任公司 一种阿齐沙坦固体组合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
JPS587609B2 (ja) 1979-06-17 1983-02-10 フロイント産業株式会社 粉体薬剤のコ−テング法
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
RO118870B1 (ro) * 1996-03-29 2003-12-30 Smithkline Beecham Corporation Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice
EP1027047B1 (fr) * 1997-08-06 2006-10-04 SmithKline Beecham Corporation Complexe de l-arginine d'eprosartan a neutralisation de charge et son procede de production et de formulation

Also Published As

Publication number Publication date
AU757547B2 (en) 2003-02-27
CN1299235A (zh) 2001-06-13
NO20004502L (no) 2000-11-07
CZ20003288A3 (cs) 2001-03-14
CY1111738T1 (el) 2015-10-07
PL192545B1 (pl) 2006-11-30
HUP0101243A1 (hu) 2002-05-29
ES2366394T3 (es) 2011-10-19
EP1061803A1 (fr) 2000-12-27
PL343411A1 (en) 2001-08-13
CA2323363A1 (fr) 1999-09-16
IL138345A0 (en) 2001-10-31
BR9908691A (pt) 2000-12-26
KR20010041796A (ko) 2001-05-25
CZ303067B6 (cs) 2012-03-21
IL138345A (en) 2004-12-15
JP2002506010A (ja) 2002-02-26
NO331207B1 (no) 2011-10-31
ATE508633T1 (de) 2011-05-15
CA2323363C (fr) 2008-09-30
DK1061803T3 (da) 2011-08-29
EP1061803B1 (fr) 2011-05-11
HUP0101243A3 (en) 2005-09-28
WO1999045779A1 (fr) 1999-09-16
EP1061803A4 (fr) 2007-12-26
NO20004502D0 (no) 2000-09-08
SI1061803T1 (sl) 2011-09-30
HU228574B1 (en) 2013-04-29
NZ506700A (en) 2003-03-28
TR200002646T2 (tr) 2001-01-22
AU2890999A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
WO2000004862A3 (fr) Formulations bioameliorees comprenant de l'eprosartane dans des formes galeniques solides destinees a une administration orale
PL343411A1 (en) Novel compositions of eprosartan
MY127793A (en) Novel form of s-omeprazole.
RO118870B1 (ro) Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice
WO2001079461A3 (fr) Polypeptides a activite haloperoxydase
WO2001079458A3 (fr) Polypeptides ayant une activite d'haloperoxidase
IL140419A0 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
HK1037616A1 (en) Novel salt form of pantoprazole
WO2007081419A3 (fr) Compositions et procedes concernant des agents anti-fgf
WO2006052461A3 (fr) Nouvelles formulations d'eprosartan presentant une biodisponibilite amelioree
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
MXPA05005198A (es) Derivados de imidazoquinolina, como ligandos del receptor a3 de adenosina.
AU1218202A (en) Receptor in the ED<sub>b</sub> fibronectin domain
MY118704A (en) Process for preparation of eprosartan
ZA200005540B (en) New hydroxyindoles, their use as phosphodiestrase 4 inhibitors and method for producing same.
CA2262769A1 (fr) Boue a faible viscosite et a teneur en solides elevee
BG106078A (en) Thio-oxindole derivatives
BG105618A (en) Beta-amido and beta-sulphonamide derivatives of carboxylic acids, method for preparation and application as endothelin-receptor antagonists
FR2842516B1 (fr) Composition d'ensimage pour verranne, procede utilisant cette composition et produits resultants
JO2094B1 (en) Chips scattered in water
ID26348A (id) Proses untuk penyediaan antogonis penerima endotelin dari jenis sulfanil
UA30584A (uk) Спосіб виробництва м'ясного холодцю "асорті заливне"